SARM1 Inhibitors Market Is Projected To Witness Stunning Growth Owing To The Rising Prevalence Of Neurological Disorders
The SARM1 Inhibitors Market is comprised of novel small molecules designed to inhibit the sterile alpha and Toll/interleukin-1 receptor (TIR) motif containing 1 protein, known as SARM1. SARM1 acts as an intrinsic trigger for axonal degeneration in neurons following injury or disease. By inhibiting this protein, SARM1 inhibitors aim to provide neuroprotection and promote nerve regeneration following injury.
The global market for SARM1 inhibitors is estimated to be valued at US$ 5 Mn in 2024 and is expected to
exhibit a CAGR of 103% over the
forecast period 2024-2031.
Key Takeaways
Key players operating in the SARM1
Inhibitors Market are Disarm
Therapeutics, Nura Bio, Washington University, and Asha Therapeutics.
Disarm Therapeutics is one of the leading companies in this domain and has
several promising preclinical candidates in its pipeline.
The key opportunities in the SARM1 Inhibitors Market include its
potential application in several neurological diseases like multiple sclerosis,
spinal cord injury, and optic nerve injury where nerve degeneration plays a
prominent role. Given the success of SARM1 inhibitors in preclinical models,
leading companies are looking to expand their clinical trials to various
geographies and patient segments in the upcoming years to tap the market
potential.
Market Drivers And Restraints
There is a rising prevalence of
neurological disorders globally owing to an aging population and lifestyle
changes which is anticipated to drive the demand for effective treatment
options like SARM1 inhibitors. In preclinical studies, SARM1 inhibitors have
shown promising efficacy in reducing nerve degeneration and promoting
regeneration, positioning them as an important therapy area. However, the
success of SARM1 inhibitors in human clinical trials still needs to be
demonstrated which a key challenge remains. High development costs associated
with central nervous system drugs is another restrain for the market. Strict
regulatory pathways for approval of novel neurological drugs also poses
concerns over market access timelines.
Segment Analysis
The SARM1 Inhibitors Market is divided into two key segments - in vivo
and in vitro. The in vivo segment dominated the market in 2023 owing to high
demand for pre-clinical research activities and increasing investment in
R&D of potential therapies. Disarm Therapeutics and Nura Bio contributed
significantly to the in vivo segment revenues.
Global Analysis
North America is projected to witness the highest growth during the
forecast period followed by Europe. Increasing research funding from both
private and public bodies along with presence of prominent pharmaceutical
players in the US and Canada are fueling the market growth in North America.
The market in Asia Pacific is expected to grow at a substantial rate between
2024 to 2031 on account of expanding healthcare infrastructure, rising
healthcare spending, and growing focus on neurological disorders in China and
India. Key players are focusing on strategic collaborations and partnerships
with regional companies to strengthen their presence in high potential markets
like Asia Pacific and Middle East & Africa.
Get more insights on this topic: https://www.ukwebwire.com/sarm1-inhibitors-market-is-estimated-to-witness-high-growth-owing-to-rising-research-development-activities/
Author Bio
Vaagisha brings over three
years of expertise as a content editor in the market research domain.
Originally a creative writer, she discovered her passion for editing, combining
her flair for writing with a meticulous eye for detail. Her ability to craft
and refine compelling content makes her an invaluable asset in delivering
polished and engaging write-ups. (LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
What
Are The Key Data Covered In This SARM1 Inhibitors Market
Report?
:- Market
CAGR throughout the predicted period
:- Comprehensive
information on the aspects that will drive the SARM1 Inhibitors's growth
between 2024 and 2031.
:- Accurate
calculation of the size of the SARM1 Inhibitors and its contribution to the
market, with emphasis on the parent market
:- Realistic
forecasts of future trends and changes in consumer behaviour
:- SARM1
Inhibitors Industry Growth in North America, APAC, Europe, South America, the
Middle East, and Africa
:- A
complete examination of the market's competitive landscape, as well as
extensive information on vendors
:- Detailed
examination of the factors that will impede the expansion of SARM1 Inhibitors
vendors
FAQ’s
Q.1 What are
the main factors influencing the SARM1 Inhibitors?
Q.2 Which
companies are the major sources in this industry?
Q.3 What are
the market’s opportunities, risks, and general structure?
Q.4 Which of
the top SARM1 Inhibitors companies compare in terms of sales, revenue, and
prices?
Q.5 Which
businesses serve as the SARM1 Inhibitors’s distributors, traders, and dealers?
Q.6 How are
market types and applications and deals, revenue, and value explored?
Q.7 What
does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Comments
Post a Comment